Publications
1.
Li, Lu; Zhou, Ting; Lu, Yiwen; Chen, Jiajie; Lei, Yuqing; Wu, Qiong; Arnold, Jonathan; Becich, Michael J.; Bisyuk, Yuriy; Blecker, Saul; Chrischilles, Elizabeth A.; Christakis, Dimitri A.; Geary, Carol Reynolds; Jhaveri, Ravi; Lenert, Leslie; Liu, Mei; Mirhaji, Parsa; Morizono, Hiroki; Mosa, Abu S. M.; Onder, Ali Mirza; Patel, Ruby; Smoyer, William E.; Taylor, Bradley W.; Williams, David A.; Dixon, Bradley P.; Flynn, Joseph T.; Gluck, Caroline; Harshman, Lyndsay A.; Mitsnefes, Mark M.; Modi, Zubin J.; Pan, Cynthia G.; Patel, Hiren P.; Verghese, Priya S.; Forrest, Christopher B.; Denburg, Michelle R.; Chen, Yong
Kidney Function Following COVID-19 in Children and Adolescents Journal Article
In: JAMA Network Open, vol. 8, iss. 4, pp. e254129, 2025.
Abstract | Links | BibTeX | Tags: COVID-19, kidney function, pediatrics
@article{nokey,
title = {Kidney Function Following COVID-19 in Children and Adolescents},
author = {Lu Li and Ting Zhou and Yiwen Lu and Jiajie Chen and Yuqing Lei and Qiong Wu and Jonathan Arnold and Michael J. Becich and Yuriy Bisyuk and Saul Blecker and Elizabeth A. Chrischilles and Dimitri A. Christakis and Carol Reynolds Geary and Ravi Jhaveri and Leslie Lenert and Mei Liu and Parsa Mirhaji and Hiroki Morizono and Abu S. M. Mosa and Ali Mirza Onder and Ruby Patel and William E. Smoyer and Bradley W. Taylor and David A. Williams and Bradley P. Dixon and Joseph T. Flynn and Caroline Gluck and Lyndsay A. Harshman and Mark M. Mitsnefes and Zubin J. Modi and Cynthia G. Pan and Hiren P. Patel and Priya S. Verghese and Christopher B. Forrest and Michelle R. Denburg and Yong Chen},
doi = {10.1001/jamanetworkopen.2025.4129},
year = {2025},
date = {2025-04-01},
urldate = {2025-04-01},
journal = {JAMA Network Open},
volume = {8},
issue = {4},
pages = {e254129},
abstract = {Importance: It remains unclear whether children and adolescents with SARS-CoV-2 infection are at heightened risk for long-term kidney complications.
Objective: To investigate whether SARS-CoV-2 infection is associated with an increased risk of postacute kidney outcomes among pediatric patients, including those with preexisting kidney disease or acute kidney injury (AKI).
Design, setting, and participants: This retrospective cohort study used data from 19 health institutions in the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) initiative from March 1, 2020, to May 1, 2023 (follow-up ≤2 years completed December 1, 2024; index date cutoff, December 1, 2022). Participants included children and adolescents (aged <21 years) with at least 1 baseline visit (24 months to 7 days before the index date) and at least 1 follow-up visit (28 to 179 days after the index date).
Exposures: SARS-CoV-2 infection, determined by positive laboratory test results (polymerase chain reaction, antigen, or serologic) or relevant clinical diagnoses. A comparison group included children with documented negative test results and no history of SARS-CoV-2 infection.
Main outcomes and measures: Outcomes included new-onset chronic kidney disease (CKD) stage 2 or higher or CKD stage 3 or higher among those without preexisting CKD; composite kidney events (≥50% decline in estimated glomerular filtration rate [eGFR], eGFR ≤15 mL/min/1.73 m2, dialysis, transplant, or end-stage kidney disease diagnosis), and at least 30%, 40%, or 50% eGFR decline among those with preexisting CKD or acute-phase AKI. Hazard ratios (HRs) were estimated using Cox proportional hazards regression models with propensity score stratification.
Results: Among 1 900 146 pediatric patients (487 378 with and 1 412 768 without COVID-19), 969 937 (51.0%) were male, the mean (SD) age was 8.2 (6.2) years, and a range of comorbidities was represented. SARS-CoV-2 infection was associated with higher risk of new-onset CKD stage 2 or higher (HR, 1.17; 95% CI, 1.12-1.22) and CKD stage 3 or higher (HR, 1.35; 95% CI, 1.13-1.62). In those with preexisting CKD, COVID-19 was associated with an increased risk of composite kidney events (HR, 1.15; 95% CI, 1.04-1.27) at 28 to 179 days. Children with acute-phase AKI had elevated HRs (1.29; 95% CI, 1.21-1.38) at 90 to 179 days for composite outcomes.
Conclusions and relevance: In this large US cohort study of children and adolescents, SARS-CoV-2 infection was associated with a higher risk of adverse postacute kidney outcomes, particularly among those with preexisting CKD or AKI, suggesting the need for vigilant long-term monitoring.},
keywords = {COVID-19, kidney function, pediatrics},
pubstate = {published},
tppubtype = {article}
}
Importance: It remains unclear whether children and adolescents with SARS-CoV-2 infection are at heightened risk for long-term kidney complications.
Objective: To investigate whether SARS-CoV-2 infection is associated with an increased risk of postacute kidney outcomes among pediatric patients, including those with preexisting kidney disease or acute kidney injury (AKI).
Design, setting, and participants: This retrospective cohort study used data from 19 health institutions in the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) initiative from March 1, 2020, to May 1, 2023 (follow-up ≤2 years completed December 1, 2024; index date cutoff, December 1, 2022). Participants included children and adolescents (aged <21 years) with at least 1 baseline visit (24 months to 7 days before the index date) and at least 1 follow-up visit (28 to 179 days after the index date).
Exposures: SARS-CoV-2 infection, determined by positive laboratory test results (polymerase chain reaction, antigen, or serologic) or relevant clinical diagnoses. A comparison group included children with documented negative test results and no history of SARS-CoV-2 infection.
Main outcomes and measures: Outcomes included new-onset chronic kidney disease (CKD) stage 2 or higher or CKD stage 3 or higher among those without preexisting CKD; composite kidney events (≥50% decline in estimated glomerular filtration rate [eGFR], eGFR ≤15 mL/min/1.73 m2, dialysis, transplant, or end-stage kidney disease diagnosis), and at least 30%, 40%, or 50% eGFR decline among those with preexisting CKD or acute-phase AKI. Hazard ratios (HRs) were estimated using Cox proportional hazards regression models with propensity score stratification.
Results: Among 1 900 146 pediatric patients (487 378 with and 1 412 768 without COVID-19), 969 937 (51.0%) were male, the mean (SD) age was 8.2 (6.2) years, and a range of comorbidities was represented. SARS-CoV-2 infection was associated with higher risk of new-onset CKD stage 2 or higher (HR, 1.17; 95% CI, 1.12-1.22) and CKD stage 3 or higher (HR, 1.35; 95% CI, 1.13-1.62). In those with preexisting CKD, COVID-19 was associated with an increased risk of composite kidney events (HR, 1.15; 95% CI, 1.04-1.27) at 28 to 179 days. Children with acute-phase AKI had elevated HRs (1.29; 95% CI, 1.21-1.38) at 90 to 179 days for composite outcomes.
Conclusions and relevance: In this large US cohort study of children and adolescents, SARS-CoV-2 infection was associated with a higher risk of adverse postacute kidney outcomes, particularly among those with preexisting CKD or AKI, suggesting the need for vigilant long-term monitoring.
Objective: To investigate whether SARS-CoV-2 infection is associated with an increased risk of postacute kidney outcomes among pediatric patients, including those with preexisting kidney disease or acute kidney injury (AKI).
Design, setting, and participants: This retrospective cohort study used data from 19 health institutions in the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) initiative from March 1, 2020, to May 1, 2023 (follow-up ≤2 years completed December 1, 2024; index date cutoff, December 1, 2022). Participants included children and adolescents (aged <21 years) with at least 1 baseline visit (24 months to 7 days before the index date) and at least 1 follow-up visit (28 to 179 days after the index date).
Exposures: SARS-CoV-2 infection, determined by positive laboratory test results (polymerase chain reaction, antigen, or serologic) or relevant clinical diagnoses. A comparison group included children with documented negative test results and no history of SARS-CoV-2 infection.
Main outcomes and measures: Outcomes included new-onset chronic kidney disease (CKD) stage 2 or higher or CKD stage 3 or higher among those without preexisting CKD; composite kidney events (≥50% decline in estimated glomerular filtration rate [eGFR], eGFR ≤15 mL/min/1.73 m2, dialysis, transplant, or end-stage kidney disease diagnosis), and at least 30%, 40%, or 50% eGFR decline among those with preexisting CKD or acute-phase AKI. Hazard ratios (HRs) were estimated using Cox proportional hazards regression models with propensity score stratification.
Results: Among 1 900 146 pediatric patients (487 378 with and 1 412 768 without COVID-19), 969 937 (51.0%) were male, the mean (SD) age was 8.2 (6.2) years, and a range of comorbidities was represented. SARS-CoV-2 infection was associated with higher risk of new-onset CKD stage 2 or higher (HR, 1.17; 95% CI, 1.12-1.22) and CKD stage 3 or higher (HR, 1.35; 95% CI, 1.13-1.62). In those with preexisting CKD, COVID-19 was associated with an increased risk of composite kidney events (HR, 1.15; 95% CI, 1.04-1.27) at 28 to 179 days. Children with acute-phase AKI had elevated HRs (1.29; 95% CI, 1.21-1.38) at 90 to 179 days for composite outcomes.
Conclusions and relevance: In this large US cohort study of children and adolescents, SARS-CoV-2 infection was associated with a higher risk of adverse postacute kidney outcomes, particularly among those with preexisting CKD or AKI, suggesting the need for vigilant long-term monitoring.